Stomach cancer hope: new combo targets tumors after PD-1 failure
NCT ID NCT06417892
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of fruquintinib (a drug that blocks blood vessel growth to tumors) and chemotherapy (albumin-paclitaxel), with or without a PD-1 antibody, for people with advanced stomach or gastroesophageal junction cancer whose first PD-1 treatment stopped working. The goal is to see if adding the PD-1 antibody again improves how long the cancer stays under control. About 60 adults will take part, and the study tracks side effects and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fruquintinib, albumin-paclitaxel (chemotherapy), and a PD-1 antibody
What this could lead to
If successful, this could offer a new second-line treatment option for advanced gastric cancer patients whose first PD-1 therapy stopped working.
What could go wrong
This is a small, early-phase study (60 people) in China, so results may not apply broadly. The combination adds more drugs, which could increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••